| abstract |
The invention relates to compounds according to the general formula (I), wherein the definition of the substituents A, B, D, E, R 1 and R 2 are listed in the description, and their physiologically acceptable salts, processes for the preparation of these compounds and their use as a medicine. These compounds are kinase inhibitors, in particular inhibitors of the kinase CDK2 (cyclin-dependent kinase 2). |